Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP
Rhinology Journal · 2026
DOI: 10.4193/rhin25.714 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Rhinology Journal, 2026. Verfasst von J K Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Head and Neck Surgery, Old Dominion University, Norfolk, VA, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Rhinosinusitis, Nasal Polyps, Patient Acceptance of Health Care.
Abstract (Originalsprache)
BACKGROUND: Evidence of dupilumab’s real-world effectiveness in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in US clinical practice is limited. OBJECTIVE: To investigate healthcare resource utilization (HCRU) and medication use in patients with CRSwNP before and after dupilumab initiation in real-world US clinical practice. METHODS: This retrospective observational study included adults with CRSwNP who initiated dupilumab 300 mg every 2 weeks between June 2019 and June 2022. Data including claims and electronic health records were extracted from the OM1 Real-World Data Cloud and Reg-ENT Registry. Medication use, healthcare visits, sinus procedures, and imaging were assessed during the 12 months before (baseline) and after (follow-up) dupilumab initiation. RESULTS: The study comprised 1,016 patients (mean age 53.8 years, 46.1% female). Annual mean [standard deviation] number of visits per patient was lower during follow-up vs baseline for outpatient (5.0 [5.2] vs 7.1 [6.0]), otolaryngologist (3.7 [6.7] vs 4.0 [6.1]) and emergency department visits (0.1 [0.6] vs 0.2 [0.6]). The proportion of patients prescribed oral corticosteroids for any reason was lower during follow-up (28.7% vs 68.1%, respectively. Fewer patients were prescribed antibiotics (31.8% vs 64.6%) and CRSwNP related oral corticosteroids (17.7% vs 59.1%), and fewer patients underwent nasal endoscopy (47.5% vs 71.2%) and CT scan (4.5% vs 22.1%) during follow-up than at baseline. CONCLUSIONS: These findings suggest an association between dupilumab treatment and reductions in HCRU and medication use in patients with CRSwNP, and provide supportive evidence of dupilumab’s real-world effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology and Head and Neck Surgery, Old Dominion University, Norfolk, VA, United States.
- Division of Otolaryngologyâ€"Head and Neck Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States.
- Division of Allergy and Immunology and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
- Department of Otolaryngologyâ€"Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, United States.
- Global Medical Affairs, Sanofi, Dubai, United Arab Emirates.
- Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, United States.
Zitieren
APA
Han, J. K., Lee, S. E., Peters, A. T., Soler, Z., Kamal, N., Nash, S., Corbett, M., Radwan, A., & Levy, J. (2026). Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP. Rhinology Journal. https://doi.org/10.4193/rhin25.714
Vancouver
Han JK, Lee SE, Peters AT, Soler Z, Kamal N, Nash S, et al. Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP. Rhinology Journal. 2026. doi:10.4193/rhin25.714
BibTeX
@article{Han2026,
author = {Han, J K and Lee, S E and Peters, A T and Soler, Z and Kamal, N and Nash, S and Corbett, M and Radwan, A and Levy, J},
title = {Real-world dupilumab treatment reduced healthcare resource utilization and medication use in patients with CRSwNP},
journal = {Rhinology Journal},
year = {2026},
doi = {10.4193/rhin25.714}
}
EUVIMED